CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 
 
 


Novan, Inc.  (NOVN)
Other Ticker:  
 
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
 
 

NOVN's Revenue Growth by Quarter and Year

Novan,'s Revenue results by quarter and year




NOVN Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - 0.62 - 0.00
III Quarter September - 0.75 - 0.00
II Quarter June - 0.67 0.00 0.00
I Quarter March 0.66 0.10 0.00 0.00
FY   0.66 2.14 - -



NOVN Revenue first quarter 2018 Y/Y Growth Comment
Novan, Inc. showed record Revenue surge in the first quarter with 558% from the first quarter 2017, to $ 0.66 millions.
This represents worst decline in recent Company history.

Looking into first quarter results within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Revenue growth. While Novan, Inc.' s Revenue doubling of 558% ranks overall at the positon no. 69 in the first quarter.




NOVN Revenue ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March 558 % - - -
FY   - - - -

Financial Statements
Novan,'s first quarter 2018 Revenue $ 0.66 millions NOVN's Income Statement
Novan,'s first quarter 2017 Revenue $ 0.10 millions Quarterly NOVN's Income Statement
New: More NOVN's historic Revenue Growth >>


NOVN Revenue (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - -17.33 % - -
III Quarter September - 11.94 % - -
II Quarter June - 570 % - -
I Quarter March 6.13 % - - -
FY (Year on Year)   - - - -




Revenue first quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #25
Overall #69

Revenue Y/Y Growth Statistics
High Average Low
558 % 558 % 558 %
(Mar 31 2018)  
Revenue first quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #25
Overall #69
Revenue Y/Y Growth Statistics
High Average Low
558 % 558 % 558 %
(Mar 31 2018)  

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018
You need to upgrade your Flash Player

Novan,'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
569 % 142.47 % -17.2 %
(Jun 30 2017)  


NOVN's I. Quarter Q/Q Revenue Comment
Novan, Inc. achieved in the I. Quarter 2018 below company average Revenue increase of 6.13% quarter on quarter, to $ 0.66 millions.

Even if the I. Quarter 2018 NOVN's performance was below the average , that was still promising story, as the current surge, eclipses the % Revenue rise in the I. Quarter a year ago

Within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Novan,'s Revenue growth quarter on quarter, overall rank is 1218.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #188
Overall #1218
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #188
Overall #1218
Revenue Q/Q Growth Statistics
High Average Low
569 % 142.47 % -17.2 %
(Jun 30 2017)  


NOVN's I. Quarter Q/Q Revenue Comment
Novan, Inc. achieved in the I. Quarter 2018 below company average Revenue increase of 6.13% quarter on quarter, to $ 0.66 millions.

I. Quarter 2018 Novan,'s results were paradoxical, although below the regular growth of 142.47 %, yet it demonstrates a quite acceleration relative to the % in the same quarter a year ago Émilie Jacobs, an industry researcher from Brussel mentioned.

Within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Novan,'s Revenue growth quarter on quarter, overall rank is 1218.


Novan,'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
12 Months Ending
(Jun 30 2017)
12 Months Ending
(Mar 31 2017)
Cumulative Revenue 12 Months Ending $ 2.70 $ 2.14 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 26.07 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 181 # 0 # 0 # 0 # 0




Cumulative Revenue growth Comment
Novan, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 558% year on year, to $ 3 millions if the fiscal year would have ended in Mar 31 2018.
Novan,'s trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2017. And, Novan, realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But sequential increase was less at 26.07 % from $2.14 millions achieved in twelve months ending a quarter before.

Novan, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
26.07 %
26.07 %
26.07 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 49
S&P 500 # 181
Cumulative Revenue growth Comment
Novan, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 558% year on year, to $ 3 millions if the fiscal year would have ended in Mar 31 2018.
Novan,'s trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2017. And, Novan, realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from the previous reporting period growth rate was beneth at 26.07 % from $2.14 millions recorded in twelve months ending a quarter Dec 31 2017 Émilie Jacobs went on.
The growth was much more impressive from the previous reporting period exhibited at 26.07 % rise from $2.14 millions in the period from Dec 31 2017 to Mar 31 2017.

Novan, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
26.07 %
26.07 %
26.07 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 49
S&P 500 # 181


You need to upgrade your Flash Player




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NOVN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NOVN's Competitors
Revenue Growth for Novan,'s Suppliers
Revenue Growth for NOVN's Customers

You may also want to know
NOVN's Annual Growth Rates NOVN's Profitability Ratios NOVN's Asset Turnover Ratio NOVN's Dividend Growth
NOVN's Roe NOVN's Valuation Ratios NOVN's Financial Strength Ratios NOVN's Dividend Payout Ratio
NOVN's Roa NOVN's Inventory Turnover Ratio NOVN's Growth Rates NOVN's Dividend Comparisons



Companies with similar Revenue increase for the quarter ending Mar 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2018
Genesis Healthcare, Inc.  953.41 %$ 953.406 millions
Miragen Therapeutics, Inc.  935.50 %$ 935.498 millions
Alpha Network Alliance Ventures Inc.  846.39 %$ 846.392 millions
Apollo Medical Holdings, Inc.  741.32 %$ 741.324 millions
Novan, Inc.  558.00 %$ 558.000 millions
Arbutus Biopharma Corp  511.06 %$ 511.064 millions
Eyegate Pharmaceuticals Inc  493.94 %$ 493.939 millions
Editas Medicine, Inc.  475.81 %$ 475.806 millions
Biolargo, Inc.  471.59 %$ 471.591 millions
Assembly Biosciences, Inc.  420.93 %$ 420.927 millions
Enanta Pharmaceuticals Inc  391.67 %$ 391.673 millions
Tracon Pharmaceuticals, Inc.  379.23 %$ 379.233 millions
Proteo Inc  363.82 %$ 363.819 millions
Nabriva Therapeutics Plc  350.00 %$ 350.000 millions
Prophase Labs, Inc.  341.89 %$ 341.894 millions
Northsight Capital, Inc.  303.25 %$ 303.254 millions
Amicus Therapeutics Inc  300.48 %$ 300.480 millions
Sarepta Therapeutics, Inc.  295.32 %$ 295.325 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PLYZ's Profile

Stock Price

PLYZ's Financials

Business Description

Fundamentals

Charts & Quotes

PLYZ's News

Suppliers

PLYZ's Competitors

Customers & Markets

Economic Indicators

PLYZ's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071